RxDoctor Payments Data

Carolyn Cutney, MD

Ophthalmology · Marlton, NJNPI 1740219310

Payments from drug & device makers

$862in general payments, 2019–2025

Across 28 payments — averaging $30.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$242
  • Kala Pharmaceuticals, Inc.$213
  • Bausch & Lomb Americas Inc.$112
  • Oyster Point Pharma, Inc.$101
  • NEW World Medical,inc.$69
  • Alcon$58
  • plus $68 from 3 others

What the payments were for

  • Food & beverage$862100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$862 in reported general payments places this provider in the 35th percentile of 583 ophthalmology providers in New Jersey.

See all ophthalmology providers in New Jersey

Medicare billing

Part B allowed, 2024
$282,608
Medicare patients
787
Services billed
1,918

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine43$56,725
XiidraLifitegrast39$40,829
TyrvayaVarenicline Tartrate29$38,316
MieboPerfluorohexyloctane/Pf25$28,964
Cyclosporine32$26,255
CequaCyclosporine12$17,069
LumiganBimatoprost25$16,954
TafluprostTafluprost/Pf47$13,296
Bromfenac Sodium43$10,373
SimbrinzaBrinzolamide/Brimonidine Tart23$9,302
RhopressaNetarsudil Mesylate16$7,794
Prednisolone Acetate236$6,944
Brimonidine Tartrate52$6,531
ProlensaBromfenac Sodium18$6,247
CombiganBrimonidine Tartrate/Timolol12$4,957

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$15$78,63680 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$112$69,79264 claims
Oyster Point Pharma, Inc.Tyrvaya$101$38,31629 claims
AlconSimbrinza$58$9,30223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 583 ophthalmology providers in New Jersey.

Other ophthalmology in Marlton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →